

France MentrÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5767459/publications.pdf>

Version: 2024-02-01

91
papers

6,618
citations

94433

37
h-index

69250

77
g-index

98
all docs

98
docs citations

98
times ranked

9963
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221. | 9.1 | 233 |
| 2 | High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea. <i>IDCases</i> , 2022, 27, e01412. | 0.9 | 2 |
| 3 | Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412. | 3.0 | 25 |
| 4 | Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 906-918. | 2.5 | 4 |
| 5 | Modeling the Effect of DAV132, a Novel Colon-Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1045-1054. | 4.7 | 11 |
| 6 | Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 2149-2159. | 5.0 | 35 |
| 7 | A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 908-917. | 1.6 | 2 |
| 8 | Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 181 |
| 9 | SARS-CoV-2 viral dynamics in non-human primates. <i>PLoS Computational Biology</i> , 2021, 17, e1008785. | 3.2 | 41 |
| 10 | Welcome to the statistics and pharmacometrics themed issue. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 273-274. | 2.5 | 1 |
| 11 | Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 340-349. | 2.5 | 1 |
| 12 | Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure. <i>AAPS Journal</i> , 2021, 23, 75. | 4.4 | 3 |
| 13 | Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1041.e1-1041.e4. | 6.0 | 88 |
| 14 | CPT: Pharmacometrics & Systems Pharmacology "Inception, Maturation, and Future Vision. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 649-657. | 2.5 | 6 |
| 15 | Finding optimal design in nonlinear mixed effect models using multiplicative algorithms. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 207, 106126. | 4.7 | 3 |
| 16 | Tutorial for \$DESIGN in NONMEM: Clinical Trial Evaluation and Optimization. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , . | 2.5 | 4 |
| 17 | Robust designs in longitudinal studies accounting for parameter and model uncertainties " application to count data. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 31-45. | 0.8 | 4 |
| 18 | Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes. <i>Statistical Methods in Medical Research</i> , 2020, 29, 934-952. | 1.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Pharmacometrics and Systems Pharmacology 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 76-78. | 4.7 | 18 |
| 20 | Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 686-694. | 2.5 | 1 |
| 21 | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514. | 2.5 | 170 |
| 22 | Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 770-772. | 9.1 | 40 |
| 23 | Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. <i>Antiviral Research</i> , 2020, 177, 104758. | 4.1 | 10 |
| 24 | Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271. | 2.5 | 20 |
| 25 | Clinical and virological data of the first cases of COVID-19 in Europe: a case series. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 697-706. | 9.1 | 953 |
| 26 | The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008259. | 3.0 | 13 |
| 27 | Model Averaging in Viral Dynamic Models. <i>AAPS Journal</i> , 2020, 22, 48. | 4.4 | 12 |
| 28 | Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM. <i>AAPS Journal</i> , 2020, 22, 50. | 4.4 | 5 |
| 29 | Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 188-188. | 4.7 | 34 |
| 30 | Type 1 interferons as a potential treatment against COVID-19. <i>Antiviral Research</i> , 2020, 178, 104791. | 4.1 | 425 |
| 31 | Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 35 |
| 32 | Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 810-820. | 4.7 | 27 |
| 33 | <i>CPT: Pharmacometrics & Systems Pharmacology</i> 2.0. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 195-196. | 2.5 | 0 |
| 34 | Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharmaceutical Statistics</i> 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873. <i>Pharmaceutical Statistics</i> , 2019, 18, 278-281. | 1.3 | 1 |
| 35 | Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 3.2 | 41 |
| 36 | PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 156, 217-229. | 4.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Protection of the Human Gut Microbiome From Antibiotics. <i>Journal of Infectious Diseases</i> , 2018, 217, 628-636. | 4.0 | 124 |
| 38 | Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013. | 12.8 | 54 |
| 39 | Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of <i>Clostridium difficile</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 18 |
| 40 | Lessons learned from IDeAl – 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 77. | 2.7 | 22 |
| 41 | Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535. | 8.4 | 108 |
| 42 | Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations. <i>Antiviral Research</i> , 2017, 140, 95-105. | 4.1 | 13 |
| 43 | Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification. <i>Pharmaceutical Research</i> , 2017, 34, 2119-2130. | 3.5 | 3 |
| 44 | Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced <i>Clostridium difficile</i> Colitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 19 |
| 45 | Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 59 |
| 46 | A new method for evaluation of the Fisher information matrix for discrete mixed effect models using Monte Carlo sampling and adaptive Gaussian quadrature. <i>Computational Statistics and Data Analysis</i> , 2017, 111, 203-219. | 1.2 | 12 |
| 47 | Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 87-109. | 2.5 | 261 |
| 48 | Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389. | 3.0 | 153 |
| 49 | Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer. <i>BMC Medical Research Methodology</i> , 2017, 17, 105. | 3.1 | 28 |
| 50 | Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967. | 8.4 | 382 |
| 51 | Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice. <i>AAPS Journal</i> , 2016, 18, 1233-1243. | 4.4 | 9 |
| 52 | An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models. <i>Biostatistics</i> , 2016, 17, 737-750. | 1.5 | 13 |
| 53 | Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 907-923. | 3.5 | 135 |
| 54 | Favipiravir for children with Ebola. <i>Lancet</i> , The, 2015, 385, 603-604. | 13.7 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Dose regimen of favipiravir for Ebola virus disease. <i>Lancet Infectious Diseases</i> , 2015, 15, 150-151. | 9.1 | 86 |
| 56 | Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 6-17. | 2.4 | 65 |
| 57 | Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches. <i>AAPS Journal</i> , 2015, 17, 691-699. | 4.4 | 38 |
| 58 | Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology. <i>Pharmaceutical Research</i> , 2015, 32, 3159-3169. | 3.5 | 10 |
| 59 | Ebola virus dynamics in mice treated with favipiravir. <i>Antiviral Research</i> , 2015, 123, 70-77. | 4.1 | 57 |
| 60 | Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted. <i>PLoS Computational Biology</i> , 2014, 10, e1003840. | 3.2 | 32 |
| 61 | Influence of Covariance Between Random Effects in Design for Nonlinear Mixed-Effect Models with an Illustration in Pediatric Pharmacokinetics. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 471-492. | 0.8 | 7 |
| 62 | Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 15-33. | 1.8 | 53 |
| 63 | Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature. <i>Computational Statistics and Data Analysis</i> , 2014, 80, 57-69. | 1.2 | 11 |
| 64 | Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1022-1034. | 2.4 | 34 |
| 65 | Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose-Response Models. <i>AAPS Journal</i> , 2012, 14, 420-432. | 4.4 | 42 |
| 66 | Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 499-518. | 1.8 | 23 |
| 67 | Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models. <i>Statistics in Medicine</i> , 2012, 31, 1043-1058. | 1.6 | 18 |
| 68 | Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 46, 34-38. | 1.4 | 19 |
| 69 | Maximum Likelihood Estimation of Long-Term HIV Dynamic Models and Antiviral Response. <i>Biometrics</i> , 2011, 67, 250-259. | 1.4 | 39 |
| 70 | Implementation and Evaluation of the SAEM Algorithm for Longitudinal Ordered Categorical Data with an Illustration in Pharmacokinetics-Pharmacodynamics. <i>AAPS Journal</i> , 2011, 13, 44-53. | 4.4 | 24 |
| 71 | Design evaluation and optimization for models of hepatitis C viral dynamics. <i>Statistics in Medicine</i> , 2011, 30, 1045-1056. | 1.6 | 14 |
| 72 | Evaluation of different tests based on observations for external model evaluation of population analyses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 49-65. | 1.8 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 98, 55-65. | 4.7 | 68 |
| 74 | Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. <i>Clinical Pharmacokinetics</i> , 2010, 49, 17-45. | 3.5 | 140 |
| 75 | Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria. <i>Journal of Infectious Diseases</i> , 2009, 200, 390-398. | 4.0 | 105 |
| 76 | Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model. <i>Statistics in Medicine</i> , 2009, 28, 1940-1956. | 1.6 | 28 |
| 77 | Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 90, 154-166. | 4.7 | 370 |
| 78 | Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?. <i>Clinical Pharmacokinetics</i> , 2007, 46, 221-234. | 3.5 | 149 |
| 79 | Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. <i>Statistics in Medicine</i> , 2007, 26, 5162-5179. | 1.6 | 55 |
| 80 | Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 229-249. | 1.8 | 135 |
| 81 | Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model. <i>Computational Statistics and Data Analysis</i> , 2006, 51, 1562-1574. | 1.2 | 126 |
| 82 | Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide. <i>Pharmaceutical Research</i> , 2006, 23, 2036-2049. | 3.5 | 268 |
| 83 | Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 345-367. | 1.8 | 94 |
| 84 | Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 161-183. | 1.8 | 87 |
| 85 | Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). <i>Antiviral Therapy</i> , 2004, 9, 247-56. | 1.0 | 5 |
| 86 | Once-Daily Dosing of Saquinavir Soft-Gel Capsules and Ritonavir Combination in HIV-1-Infected Patients (Imea015 Study). <i>Antiviral Therapy</i> , 2004, 9, 247-256. | 1.0 | 15 |
| 87 | Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 209-227. | 0.8 | 87 |
| 88 | The use of simulated annealing for finding optimal population designs. <i>Computer Methods and Programs in Biomedicine</i> , 2002, 69, 25-35. | 4.7 | 49 |
| 89 | Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. <i>Statistics in Medicine</i> , 2002, 21, 2623-2639. | 1.6 | 65 |
| 90 | Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. <i>Computer Methods and Programs in Biomedicine</i> , 2001, 65, 141-151. | 4.7 | 122 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 133-161. | 0.6 | 28 |